Primary studies included in this broad synthesis

loading
6 articles (6 References) loading Revert Studify

Primary study

Unclassified

Complex partial seizure symptoms affected by marijuana abuse.

blocked
Authors Ellison JM , Gelwan E , Ogletree J
Journal The Journal of clinical psychiatry
Year 1990
Links Pubmed
Loading references information

Primary study

Unclassified

Double-blind clinical study of cannabidiol as a secondary anticonvulsant

blocked
Authors Trembly B , Sherman M
Conference Marijuana '90 International Conference on Cannabis and Cannabinoids. Kolympari, Crete. International Association for Cannabinoid Medicines
Year 1990
Links www.gwpharm.com Google Scholar
Loading references information
This project was designed to evaluate the anticonvulsant activity of cannabidiol (CBD) in a group of twelve adult incompletely-controlled outpatients in a double-blind, cross-over, placebo-controlled, add-on study lasting two years. Effects of chronic CBD administration upon seizure frecuency and character, hematologic, renall and liver function, levels of existing anticonvulsant medications and upon neuropsychologic function were evaluated.

Primary study

Unclassified

Anticonvulsant effect of cannabidiol.

Authors Ames FR , Cridland S
Journal South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
Year 1986
Links Pubmed
Loading references information

Primary study

Unclassified

Chronic administration of cannabidiol to healthy volunteers and epileptic patients.

Journal Pharmacology
Year 1980
Links Pubmed DOI
Loading references information
In phase 1 of the study, 3 mg/kg daily of cannabidiol (CBD) was given for 30 days to 8 health human volunteers. Another 8 volunteers received the same number of identical capsules containing glucose as placebo in a double-blind setting. Neurological and physical examinations, blood and urine analysis, ECG and EEG were performed at weekly intervals. In phase 2 of the study, 15 patients suffering from secondary generalized epilepsy with temporal focus were randomly divided into two groups. Each patient received, in a double-blind procedure, 200-300 mg daily of CBD or placebo. The drugs were administered for along as 4 1/2 months. Clinical and laboratory examinations, EEG and ECG were performed at 15- or 30-day intervals. Throughout the experiment the patients continued to take the antiepileptic drugs prescribed before the experiment, although these drugs no longer controlled the signs of the disease. All patients and volunteers tolerated CBD very well and no signs of toxicity or serious side effects were detected on examination. 4 of the 8 CBD subjects remained almost free of convulsive crises throughout the experiment and 3 other patients demonstrated partial improvement in their clinical condition. CBD was ineffective in 1 patient. The clinical condition of 7 placebo patients remained unchanged whereas the condition of 1 patient clearly improved. The potential use of CBD as an antiepileptic drug and its possible potentiating effect on other antiepileptic drugs are discussed.

Primary study

Unclassified

Toward drugs derived from cannabis.

Authors Mechoulam R , Carlini EA
Journal Die Naturwissenschaften
Year 1978
Links Pubmed DOI
Loading references information
Recent work aimed at the introduction of natural and synthetic cannabinoids as drugs is reviewed. Delta1-Tetrahydrocannabinol (delta1-THC) is mainly investigated as a potential drug against glaucoma and asthma, and as an antiemetic agent in cancer chemotherapy. Cannabidiol is being tried in the clinic against epilepsy and as a hypnotic. Numerous synthetic cannabinoids are currently being investigated as analgetics and as sedative-relaxants.

Primary study

Unclassified

Anticonvulsant nature of marihuana smoking.

blocked
Authors Consroe PF , Wood GC , Buchsbaum H
Journal JAMA
Year 1975
Links Pubmed
Loading references information
Marihuana smoking, in conjunction with therapeutic doses of phenobarbital and diphenylhydantoin, was apparently necessary for controlling seizures in one 24-year-old epileptic patient.